Hepatic Veno-Occlusive Disease
"Hepatic Veno-Occlusive Disease" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Liver disease that is caused by injuries to the ENDOTHELIAL CELLS of the vessels and subendothelial EDEMA, but not by THROMBOSIS. Extracellular matrix, rich in FIBRONECTINS, is usually deposited around the HEPATIC VEINS leading to venous outflow occlusion and sinusoidal obstruction.
|Hepatic Veno-Occlusive Disease
- Hepatic Veno-Occlusive Disease
- Disease, Hepatic Veno-Occlusive
- Hepatic Veno-Occlusive Diseases
- Sinusoidal Obstruction Syndrome
- Syndrome, Sinusoidal Obstruction
- Hepatic Veno Occlusive Disease
- Veno-Occlusive Disease, Hepatic
- Veno Occlusive Disease, Hepatic
Below are MeSH descriptors whose meaning is more general than "Hepatic Veno-Occlusive Disease".
Below are MeSH descriptors whose meaning is more specific than "Hepatic Veno-Occlusive Disease".
This graph shows the total number of publications written about "Hepatic Veno-Occlusive Disease" by people in this website by year, and whether "Hepatic Veno-Occlusive Disease" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Hepatic Veno-Occlusive Disease" by people in Profiles.
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019 07 15; 125(14):2474-2487.
Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE. Cancer. 2018 04 15; 124(8):1722-1732.
Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant. 2018 04; 53(4):449-456.
Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies. Biol Blood Marrow Transplant. 2016 08; 22(8):1424-1430.
Atypical acute liver failure in acute myeloid leukemia. Gastroenterology. 2014 Sep; 147(3):e3-4.
Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant. Leuk Lymphoma. 2012 Aug; 53(8):1552-7.
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Leuk Lymphoma. 2010 Dec; 51(12):2240-9.
Acute sinusoidal obstruction syndrome after 6-thioguanine therapy for Crohn's disease. Inflamm Bowel Dis. 2004 Sep; 10(5):652-4.
Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease. Ann Oncol. 2004 Aug; 15(8):1231-6.
Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia. Bone Marrow Transplant. 1999 May; 23(10):977-81.